The 2023-2028 Outlook for Non-Instant Long Grain Rice for US Zip Codes

This study covers the latent demand outlook for non-instant long grain rice across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip c...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Noninvasive Cancer Diagnostics for US Zip Codes

This study covers the latent demand outlook for noninvasive cancer diagnostics across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zi...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Invasive Aesthetic Treatments for US Zip Codes

This study covers the latent demand outlook for non-invasive aesthetic treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Invasive Fat Reduction Technologies for US Zip Codes

This study covers the latent demand outlook for non-invasive fat reduction technologies across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. Fo...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Interest Commercial Banking for US Zip Codes

This study covers the latent demand outlook for non-interest commercial banking across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each z...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Infectious Macular Edema Treatments for US Zip Codes

This study covers the latent demand outlook for non-infectious macular Edema treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. Fo...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Hodgkin Lymphoma for US Zip Codes

This study covers the latent demand outlook for non-Hodgkin lymphoma across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in ...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Hodgkin's Lymphoma and Chronic Lymphoma Treatments for US Zip Codes

This study covers the latent demand outlook for non-Hodgkin's lymphoma and chronic lymphoma treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the Un...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Treatments for US Zip Codes

This study covers the latent demand outlook for non-Hodgkin lymphoma treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each z...

1/9/2023 | the United States Outlook 2023

The 2023-2028 Outlook for Non-Hodgkin Lymphoma Chemotherapy Therapeutics for US Zip Codes

This study covers the latent demand outlook for non-Hodgkin lymphoma chemotherapy therapeutics across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United Sta...

1/9/2023 | the United States Outlook 2023

This study covers the latent demand outlook for non-instant long grain rice across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-instant long grain rice. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-instant long grain rice as including all commonly understood products and/or services falling within this broad category, such as brown and white varieties of light unsticky rice with kernels that are three times longer than they are wide, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Hinode and Mahatma. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for noninvasive cancer diagnostics across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for noninvasive cancer diagnostics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of noninvasive cancer diagnostics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include A&G Pharmaceutical, Affymetrix, Aviva Biosciences, BIOVIEW, Cancer Genetics, Celsee Diagnostics, DiaDx, EONE-DIAGNOSTICS Genome Center, Exosome Sciences, Gen-Probe Inc.,Digene Corporation, iCellate Medical, Inivata, IVDiagnostics, Laboratory Corporation of America Holdings (LabCorp), LCM Genect, Menarini Silicon Biosystems, Myriad Genetics, Precision Therapeutics, Qiagen, Quest Diagnostics, Roche, Siemens Healthineers, and Thermo Fisher Scientific. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-invasive aesthetic treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-invasive aesthetic treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-invasive aesthetic treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Allergan, Alma Lasers, Anika Therapeutics, Candela, Cutera, Cynosure, Fotona, Galderma, Hologic, Johnson & Johnson, Lumenis, Merz Pharma, Nestlé Skin Health, OrangeTwist Aesthetic Centers, Revance Therapeutics, Sinclair Pharma, Solta Medical, Syneron Candela, Venus Concept, and Vermont Med Spa. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-invasive fat reduction technologies across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-invasive fat reduction technologies. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-invasive fat reduction technologies as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Alma Lasers, BTL Medical Technologies Pty, Ltd., Cutera, Cynosure, Lumenis, Solta Medical, Syneron Medical, and Venus Concept. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-interest commercial banking across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-interest commercial banking. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-interest commercial banking as including all commonly understood services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bank of America, Citigroup, JP Morgan Chase, Wachovia, and Wells Fargo. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-infectious macular Edema treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-infectious macular Edema treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-infectious macular Edema treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Alimera Sciences, Allergan, Amgen, Bausch Health Companies, Bayer, Clearside Biomedical, F. Hoffman - La Roche, Novartis, Pfizer, and Valeant Pharmaceuticals International. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-Hodgkin lymphoma across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-Hodgkin lymphoma. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-Hodgkin lymphoma as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Baxter, Bayer, Bristol-Myers Squibb, Eli Lilly the Company, F. Hoffmann-La Roche, Gilead Sciences, Inc. (US), GlaxoSmithKline, Johnson & Johnson, Merck & Company, Novartis, Ono Pharmaceutical Company, Pfizer, Pharmacyclics, Seattle Genetics, Syndax, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, TG Therapeutics, and Verastem Oncology. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-Hodgkin's lymphoma and chronic lymphoma treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-Hodgkin's lymphoma and chronic lymphoma treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-Hodgkin's lymphoma and chronic lymphoma treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 4SC, Accredo Health Group, Inc., Agios, Aileron Therapeutics, Allinky Biopharma SL, Amgen, AstraZeneca, Baxter, Bayer, Bristol-Myers-Squibb, Celgene Corporation, Eisai Company, Eli Lilly and Company, F. Hoffman-La Roche, Gilead, GlaxoSmithKline, Immune Design, Johnson & Johnson, Kite Pharma, Merck, Nordic Nanovector ASA, Novartis, Pharmacyclics, Rescue Therapeutics, Inc., and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-Hodgkin lymphoma treatments across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-Hodgkin lymphoma treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-Hodgkin lymphoma treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, AstraZeneca, Bayer, Bristol Myers squibb Company, Celgene Corporation (Us), F. Hoffmann-La Roche, Janssen Pharmaceuticals, Kite Pharma, Kyowa Kirin Company, Merck & Company, Novartis, Sanofi, Spectrum Pharmaceuticals, Takeda Pharmaceutical Company, and Teva Pharmaceutical Industries. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

This study covers the latent demand outlook for non-Hodgkin lymphoma chemotherapy therapeutics across the states and zip codes of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 10,833 zip codes in the United States. For each zip code in question, the percent share the zip code is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a zip code vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and zip code, latent demand estimates are created for non-Hodgkin lymphoma chemotherapy therapeutics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of non-Hodgkin lymphoma chemotherapy therapeutics as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Bayer, Bristol-Myers Squibb, F. Hoffmann-La Roche, GlaxoSmithKline, Merck & Company, Novartis International, and Pfizer. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022). ...

1/9/2023

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT